

circumference) were collected. ABI measurement was performed in all patients with a 8 mHz vascular doppler to classify patients as: Normal ABI (1.0-1.4), Altered ABI (≤ 0.9 or > 1.4) and borderline ABI (0.91-0.99). Transient elastography (Fibroscan) was performed to determine steatosis and fibrosis stage. We excluded pregnant women, previously known CV disease, CLD or PAD. Descriptive statistics and comparative analysis were performed using SPSS version 24 software.

Results and Discussion: Sixty-eight patients with CV risk factors were included (48 female [70.6%] with a mean age of 47.38 years). Comorbidities were detected as follows: obesity in 52 patients (76.5%); dyslipidemia in 49 patients (72%); diabetes mellitus in 46 patients (67.6%); arterial hypertension in 35 patients (51.5%). Fifty-three patients had normal ABI (77.9%); altered ABI was found in 15 patients (22.1%). Sixty-one patients were found to have steatosis (89.7%), out of which 14 patients had fibrosis (22.9%). Comparison of both groups (altered vs. normal ABI) are presented in Table 1.

Conclusions: Patients with traditional CV risk factors showed a high rate of MASLD and similar altered ABI compared to previously described populations.

<https://doi.org/10.1016/j.aohep.2024.101721>

P-108 MAFLD-S SCORE: A CONVENIENT CLINICAL TOOL FOR PREDICTING MASLD IN PRIMARY CARE SETTINGS

JUAN ADRIÁN TORRES DÍAZ¹,
ANTONIO OLIVAS MARTÍNEZ²,
JESÚS ALEJANDRO RUIZ MANRÍQUEZ³,
LUIS FEDERICO USCANGA DOMÍNGUEZ⁴,
LUIS CARLOS CHÁVEZ GARCÍA³,
ASHUIN KAMMAR GARCÍA⁵,
SOPHIA EUGENIA MARTÍNEZ VÁZQUEZ⁴

¹ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Hepatology, Mexico city, Mexico, Ciudad de México, México

² University of Washington, Department of Biostatistics, Washington, United States of America, Washington, Estados Unidos (EEUU)

³ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Endoscopy, Mexico city, Mexico, Ciudad de México, México

⁴ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Gastroenterology, Mexico, Mexico, Ciudad de México, México

⁵ Instituto Nacional de Geriátría, Clinical Research Division, Mexico city, Mexico, Ciudad de México, México

Conflict of interest: No

Introduction and Objectives: Non-invasive methods for screening metabolic dysfunction-associated steatotic liver disease (MASLD) are gaining attention. A recent advancement in non-invasive screening is the MAFLD-S score, a tool that exclusively uses clinical data to predict the risk of MASLD.

The aim is to evaluate the performance of the MAFLD-S score to identify individuals with MASLD in a cohort of apparently healthy individuals.

Patients / Materials and Methods: A cross-sectional study was conducted including adults with unknown MASLD. A transient elastography was performed and hepatic steatosis was defined by a controlled attenuation parameter (CAP) > 248 dB/m. The MASLD criteria were assessed, and the MAFLD-S score, Fatty Liver Index (FLI) and Hepatic Steatosis Index (HSI) were calculated in each member of the

cohort. The classification accuracy of these scores was evaluated through their areas under the receiver-operating characteristic (AUROC) curves and their calibration to predict the risk of MASLD was assessed graphically.

Results and Discussion: A total of 521 participants were included, being 61% women, and the mean age was 41 years. The frequency of MASLD in the study population was 44.1%. The area under the ROC curve for MAFLD-S was 0.823 (95% CI, 0.788-0.858), for FLI was 0.841 (95% CI, 0.807-0.875) and for HSI was 0.822 (95% CI, 0.787-0.858). The calculated sensitivity for MAFLD-S score using the recommended threshold was 61% (95% CI 0.55-0.68) and specificity of 81% (95% CI 0.77-0.86), for FLI sensitivity was 62% (95% CI 0.56-0.68) and specificity was 82% (95% CI 0.78-0.87) and for HSI sensitivity was 85% (95% CI 0.80-0.89) and specificity was 61% (95% CI 0.56-0.67).

Conclusions: The MAFLD-S score, a tool that only uses clinical variables, confirmed to be a very good tool for screening MASLD in apparently healthy individuals in Mexico.

	Sensitivity	Specificity	+LR	-LR
Using recommended threshold				
MAFLD-S score	0.61 (0.55-0.68)	0.81 (0.77-0.86)	3.24 (2.50-4.20)	0.48 (0.40-0.57)
Fatty Liver Index	0.62 (0.56-0.68)	0.82 (0.78-0.87)	3.51 (2.67-4.60)	0.46 (0.39-0.55)
Hepatic Steatosis Index	0.85 (0.80-0.89)	0.61 (0.56-0.67)	2.19 (1.87-2.56)	0.25 (0.18-0.34)
Using optimal threshold in our study population				
MAFLD-S score	0.76 (0.70-0.81)	0.77 (0.72-0.81)	3.20 (2.60-4.04)	0.32 (0.25-0.40)
Fatty Liver Index	0.92 (0.89-0.96)	0.66 (0.61-0.72)	2.74 (2.32-3.24)	0.12 (0.08-0.19)
Hepatic Steatosis Index	0.72 (0.66-0.78)	0.76 (0.71-0.81)	3.00 (2.40-3.75)	0.30 (0.30-0.46)

Sensitivity and specificity for the thresholds recommended by each index and with the optimal threshold for our study population

<https://doi.org/10.1016/j.aohep.2024.101722>

P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS

Guilherme Grossi Lopes Cançado¹, Patricia Fucuta²,
Nathalia Mota de Faria Gomes³,
Claudia Alves Couto¹, Eduardo Luiz Rachid Cançado⁴,
Debora Raquel Benedita Terrabuio⁴,
Cristiane Alves Villela-Nogueira⁵,
Michelle Harriz Braga⁴, Mateus Jorge Nardelli¹,
Luciana Costa Faria¹, Elze Maria Gomes Oliveira⁶,
Vivian Rotman⁵, Maria Beatriz Oliveira⁷,
Simone Muniz Carvalho Fernandes da Cunha⁸,
MARLONE CUNHA DA SILVA⁹,
Liliana Sampaio Costa Mendes¹⁰,
Claudia Alexandra Pontes Ivantes¹¹, Liana Codes¹²,
Valéria Ferreira de Almeida e Borges¹³,
Fabio Heleno de Lima Pace¹⁴,
Mario Guimarães Pessoa⁴,
Izabelle Venturini Signorelli¹⁵,
Gabriela Perdomo Coral¹⁶,
PAULO LISBOA BITTENCOURT¹²,
Maria Lúcia Gomes Ferraz³

¹ UNIVERSIDADE FEDERAL DE MINAS GERAIS, BELO HORIZONTE, Brasil

² FACERES, SÃO JOSÉ DO RIO PRETO, Brasil

³ UNIVERSIDADE FEDERAL DE SÃO PAULO, SÃO PAULO, Brasil

⁴ UNIVERSIDADE DE SÃO PAULO, SÃO PAULO, Brasil

⁵ UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, RIO DE JANEIRO, Brasil

⁶ UNILUS, SANTOS, Brasil

⁷ AMBULATÓRIO DE HEPATITES VIRAIS DE SÃO JOSÉ DOS CAMPOS, SÃO JOSÉ DOS CAMPOS, Brasil

⁸ UNIVERSIDADE FEDERAL DA BAHIA, SALVADOR, Brasil

⁹ UNIVERSIDADE ESTADUAL DE CAMPINAS, CAMPINAS, Brasil

¹⁰ HOSPITAL DE BASE DO DISTRITO FEDERAL, BRASILIA, Brasil

¹¹ HOSPITAL NOSSA SENHORA DAS GRAÇAS, CURITIBA, Brasil

¹² HOSPITAL PORTUGUES, SALVADOR, Chile

¹³ UNIVERSIDADE FEDERAL DE UBERLÂNDIA, UBERLÂNDIA, Brasil

¹⁴ UNIVERSIDADE FEDERAL DE JUIZ DE FORA, JUIZ DE FORA, Brasil

¹⁵ UNIVERSIDADE FEDERAL DO ESPÍRITO SANTO, ESPÍRITO SANTO, Brasil

¹⁶ SANTA CASA DE MISERICÓRDIA DE PORTO ALEGRE, PORTO ALEGRE, Brasil

Conflict of interest: No

Introduction and Objectives: Primary biliary cholangitis is a chronic and progressive autoimmune liver disease, whose prognosis can be improved by normalizing alkaline phosphatase and bilirubin. While ursodeoxycholic acid (UDCA) is first line standard of care, approximately 40% of patients exhibit incomplete response. We aimed to identify prognostic markers for deep response to UDCA therapy at presentation.

Patients / Materials and Methods: Data from the Brazilian Cholestasis Study Group cohort were analyzed retrospectively. Patients were assessed for deep response (defined as normalization of alkaline phosphatase and bilirubin) after 1 year of UDCA treatment. With the purpose of selecting the set of relevant variables related to the deep response for a parsimonious multivariate model, we applied the Var-rank algorithm. Additionally, the performance of the UDCA response score in predicting deep response was evaluated.

Results and Discussion: A total of 297 patients were analyzed, with 57.2% achieving an adequate response according to the Toronto criteria, while 22.9% reached deep response. Cirrhosis (OR 0.460; 95% CI 0.225-0.942; $p=0.034$) and elevated baseline alkaline phosphatase levels (OR 0.629; 95% CI 0.513-0.770; $p<0.001$) were associated with reduced odds of deep response. The UDCA response score exhibited moderate discrimination power (AUROC=0.769) but lacked calibration.

Conclusions: Baseline ALP, and cirrhosis at diagnosis emerge as the most important prognostic factors to predict normalization of alkaline phosphatase and bilirubin after UDCA. The UDCA response score is inadequate for predicting deep response in the Brazilian PBC population.

<https://doi.org/10.1016/j.aohep.2024.101723>

P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA

Matías Sebastián Bori¹, Juan Antonio Sordá¹, Ilse Sorena Pardo Ivirico¹, Carolina Garrafa¹, Esteban González Ballerga¹

¹ Sección Hepatología, División Gastroenterología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, CABA, Argentina

Conflict of interest: No

Introduction and Objectives: The clinical presentation of primary biliary cholangitis (PBC) has changed globally over time. However, these data have not been sufficiently analyzed in our setting. **Objective:** To analyze changes in the clinical presentation of PBC over the last 40 years in a university center in Argentina.

Patients / Materials and Methods: A retrospective study including 596 patients, divided into four groups according to the year of diagnosis: <1990 (N=113), 1990-1999 (N=206), 2000-2009 (N=151), and >2009 (N=106). Variables analyzed included age at diagnosis, disease stage, clinical presentation (asymptomatic or symptomatic), biochemical stages (according to Rotterdam criteria), and histological stages.

Results and Discussion: The female-to-male ratio was 24:1 and remained stable over time. There was an increase in the mean age at diagnosis, from 54.3 years (± 11.6) before 1990 to 57.2 years (± 12.2) after 2009 ($p=0.0185$). The symptomatic clinical variant decreased from 73.7% to 50.0% ($p<0.001$), while early biochemical stage diagnosis increased from 18.0% to 77.4% ($p<0.001$) over the same period. Advanced histological stages (III-IV) decreased from 60.2% before 1990 to 20.8% after 2009 ($p<0.001$).

Conclusions: Over time, patients with PBC have shown a change in their clinical presentation, characterized by an older age at diagnosis, earlier biochemical and histological stages, and a predominance of asymptomatic clinical forms. These findings are consistent with global reports and may be attributable to better knowledge of the disease, greater availability and access to diagnostic tests, and possibly changes in environmental triggers over time.

<https://doi.org/10.1016/j.aohep.2024.101724>

P-111 CHARACTERIZATION OF PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS, IN TWO REFERENCE CENTERS, FROM 2011 TO 2023

Lorena Sofía Martínez Bogado¹, Sara Melgarejo¹, Maisa Vallejos¹, Edith Martínez¹, Claudia Crovato Jimenez¹, Sebastián Burro¹, Karina Riquelme¹, Sergio Morínigo¹, Sebastián Díaz Duba¹, Modesto Ávalos¹, Marcos Giralda Salomón¹, Jesús Ortiz Villalba¹

¹ HOSPITAL DE CLÍNICAS, San Lorenzo, Paraguay

Conflict of interest: No

Introduction and Objectives: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease, characterized by inflammation with fibrosis and obliteration of the intrahepatic and extrahepatic bile ducts. The process of chronic cholestasis eventually leads to biliary cirrhosis. It is associated with ulcerative colitis (UC) in most cases. **Objectives:** To describe clinical, laboratory and imaging characteristics of patients with PSC, in two reference centers for liver diseases, from 2011 to 2023.

Patients / Materials and Methods: Observational, descriptive, retrospective study. Excel is used for data collection. The variables were expressed in frequency, range, mean and percentage.

Results and Discussion: 16,347 records were reviewed, of which, 36 (0.22%) had the diagnosis of PSC. Four had incomplete medical records so 32 were included. Fifty nine percent were